Cue Biopharma, Inc. financial data

Symbol
CUE on Nasdaq
Industry
Pharmaceutical Preparations
Location
40 Guest Street, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Imagen Biopharma, Inc. (to 6/19/2015)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 244 % -45.6%
Debt-to-equity 77.6 % +53.7%
Return On Equity -156 % -57.7%
Return On Assets -88.1 % -33.7%
Operating Margin -479 % +65.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63.4M shares +40.4%
Common Stock, Shares, Outstanding 60.2M shares +33.4%
Entity Public Float 154M USD +88.1%
Common Stock, Value, Issued 60K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 51.2M shares +10.5%
Weighted Average Number of Shares Outstanding, Diluted 51.2M shares +10.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.53M USD +150%
Research and Development Expense 40M USD -3.03%
General and Administrative Expense 15.2M USD -3.8%
Operating Income (Loss) -45.7M USD +14.1%
Nonoperating Income (Expense) 1.09M USD -15.8%
Net Income (Loss) Attributable to Parent -44.6M USD +14%
Earnings Per Share, Basic -0.91 USD/shares +23.5%
Earnings Per Share, Diluted -0.91 USD/shares +23.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 32.4M USD -40.7%
Accounts Receivable, after Allowance for Credit Loss, Current 3.15M USD +89.8%
Assets, Current 37.3M USD -35.2%
Property, Plant and Equipment, Net 570K USD -46.4%
Operating Lease, Right-of-Use Asset 4.03M USD -42.9%
Other Assets, Noncurrent 108K USD -10%
Assets 44.8M USD -35%
Accounts Payable, Current 6.47M USD +161%
Accrued Liabilities, Current 3.2M USD -37.6%
Liabilities, Current 16.8M USD -2.42%
Operating Lease, Liability, Noncurrent 1.33M USD -65.6%
Liabilities 19.4M USD -25.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -332M USD -15.5%
Stockholders' Equity Attributable to Parent 25.4M USD -40.5%
Liabilities and Equity 44.8M USD -35%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.78M USD +9.68%
Net Cash Provided by (Used in) Financing Activities 2.35M USD +507%
Net Cash Provided by (Used in) Investing Activities -55K USD -100%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 60.2M shares +33.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.49M USD -264%
Interest Paid, Excluding Capitalized Interest, Operating Activities 209K USD -36.7%
Deferred Tax Assets, Valuation Allowance 84M USD +20%
Deferred Tax Assets, Gross 85.8M USD +18.2%
Operating Lease, Liability 4.22M USD -41.8%
Depreciation 467K USD -18.8%
Payments to Acquire Property, Plant, and Equipment 55K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -44.6M USD +13.9%
Lessee, Operating Lease, Liability, to be Paid 4.42M USD -43.5%
Property, Plant and Equipment, Gross 4.47M USD -21.6%
Operating Lease, Liability, Current 2.9M USD -14.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.8M USD -16.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 803K USD -3.83%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 199K USD -64.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 818K USD -70.8%
Deferred Tax Assets, Operating Loss Carryforwards 53.4M USD +7.38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.93M USD +17.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 818K USD
Operating Lease, Payments 709K USD +139%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 3.37M USD +39.8%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 822K USD -37.3%
Deferred Tax Assets, Net of Valuation Allowance 1.79M USD -30.8%
Share-based Payment Arrangement, Expense -816K USD +35.6%
Operating Leases, Future Minimum Payments, Due in Three Years 2.86M USD
Interest Expense 130K USD +11.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%